On Jan. 16, the Center for Human-Computer Interaction + Design convened an interdisciplinary group of bold thinkers to ...
Two separate non-GLP studies in mice and non-human primates (NHPs) assessed the safety and tolerability of CUE-401 using a step-up dosing schedule, where animals successively received higher doses of ...
Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease In the RELIEVE UCCD LTE phase 2b study, duvakitug ...
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well toler ...
In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD ...
TAMARAC, FL, UNITED STATES, February 17, 2026 /EINPresswire.com/ -- Tamarac, Florida , The OSHAccredited Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results